Selected data models

You must log in to select data models for download or further analysis.

36 Search results.
Relevance Rating New first Old first

dbGaP phs000942 Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic - Eligibility

- 11/27/24 - 5 forms, 1 itemgroup, 1 item, 1 language
Itemgroup: IG.elig
Principal Investigator: Theodora S. Ross, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA, and Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA MeSH: Neoplasms,Breast Neoplasms,Ovarian Neoplasms,Peritoneal Neoplasms,Skin Neoplasms,Esophageal Neoplasms,Thyroid Neoplasms,Urinary Bladder Neoplasms,Endometrial Neoplasms,Fallopian Tube Neoplasms,Melanoma,Testicular Neoplasms,Bile Duct Neoplasms,Lung Neoplasms,Colonic Neoplasms,Adrenocortical Carcinoma,Carcinoma, Renal Cell,Colonic Polyps,Adenomatous Polyposis Coli,Lymphoma, Large B-Cell, Diffuse,Pheochromocytoma,Paraganglioma,Leiomyoma,Hemangioblastoma,Hyperparathyroidism,Pancreatic Neoplasms,Vulvar Neoplasms,Brain Neoplasms,Liver Neoplasms,Kidney Neoplasms,Prostatic Neoplasms,Glioblastoma,Oncocytoma, renal https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000942 Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks. "Reprinted from doi:10.1016/j.ebiom.2014.12.003, with permission from EBioMedicine."

pht004834.v1.p1

1 itemgroup 5 items

pht004835.v1.p1

1 itemgroup 5 items

pht004836.v1.p1

1 itemgroup 16 items

pht004837.v1.p1

1 itemgroup 5 items

Ovarian Cancer NCT00993655 Off Treatment - NCIC OV 21 End of Treatment Form - 2874223v1.0 - NCIC OV 21 End of Treatment Form

- 1/9/15 - 1 form, 5 itemgroups, 22 items, 1 language
Itemgroups: Patient Information, OFF PROTOCOL THERAPY , CA 125 At the End of Protocol Treatment, Comments, Contact Information
NCIC OV 21 End of Treatment Form Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=69B8C40D-B831-E610-E040-BB89AD43211A

Ovarian Cancer NCT00993655 Off Treatment - NCIC OV 21 Death Report Form - 2874203v1.0 - NCIC OV 21 Death Report Form

- 1/9/15 - 1 form, 4 itemgroups, 15 items, 1 language
Itemgroups: Patient Information, DATE/CAUSE OF DEATH/AUTOPSY, Comments, Contact Information
NCIC OV 21 Death Report Form Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=69B794A7-2EA4-1666-E040-BB89AD432FB9

Ovarian Cancer NCT00993655 On-Study - NCIC OV 21 Relapse-Progression Report Form - 2874242v1.0 - NCIC OV 21 Relapse-Progression Report Form

- 1/9/15 - 1 form, 9 itemgroups, 34 items, 1 language
Itemgroups: Patient Information, TYPE OF PROGRESSION, DATE OF CA125 PROGRESSION, DISEASE STATUS AT RELAPSE-PROGRESSION, TARGET LESIONS, NON-TARGET LESIONS, NEW LESIONS, Comments, Contact Information
NCIC OV 21 Relapse-Progression Report Form Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=69B8C40D-B857-E610-E040-BB89AD43211A

Ovarian Cancer NCT00993655 Pathology - NCIC OV 21 Tumour Tissue Banking Information Report Form - 2874201v1.0 - NCIC OV 21 Tumour Tissue Banking Information Report Form

- 1/9/15 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Patient Information, TUMOUR TISSUE BANKING INFORMATION
NCIC OV 21 Tumour Tissue Banking Information Report Form Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=69B794A7-2EA0-1666-E040-BB89AD432FB9

Ovarian Cancer NCT00993655 Eligibility - NCIC OV 21 Eligibility Worksheet Form - 2888929v1.0 - NCIC OV 21 Eligibility Worksheet Form

- 1/9/15 - 1 form, 6 itemgroups, 34 items, 1 language
Itemgroups: Patient Information, ELIGIBILITY WORKSHEET, ELIGIBILITY LABS, ELIGIBILITY WORKSHEET1, Comments, Contact Information
NCIC OV 21 Eligibility Worksheet Form Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6AC1EB4E-A50F-6962-E040-BB89AD430850

Cycle Dose Drug Form (D2R) GOG-0241

- 8/22/15 - 1 form, 3 itemgroups, 42 items, 1 language
Itemgroups: HEADER MODULE, TREATMENT CYCLE AND MODIFICATION, Pretreatment hematology and chemistry values
GOG-0241 Cycle Dose Drug Form (D2R) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=

Ovarian Cancer NCT00993655 Follow-Up - NCIC OV 21 Follow-Up Report Form - 2874229v1.0 - NCIC OV 21 Follow-Up Report Form

- 1/9/15 - 1 form, 14 itemgroups, 60 items, 1 language
Itemgroups: Patient Information, TIMING OF REPORT, PHYSICAL EXAM, RESPONSE ASSESSMENT - QUESTION 2, TARGET LESIONS, NON-TARGET LESIONS DURING TREATMENT, NEW LESIONS, RADIOLOGY, CA 125 - TABLE, ADVERSE EVENTS / INTERCURRENT ILLNESS, ANTI-CANCER TREATMENT, QUALITY OF LIFE QUESTIONNAIRE, Comments, Contact Information
NCIC OV 21 Follow-Up Report Form Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=69B8C40D-B83D-E610-E040-BB89AD43211A

Cycle Dose Drug Form (D2R) GOG-0262

- 8/22/15 - 1 form, 4 itemgroups, 38 items, 1 language
Itemgroups: HEADER MODULE, TREATMENT CYCLE AND MODIFICATION, Pretreatment hematology and chemistry values, COMMENTS
Cycle Dose Drug Form (D2R) GOG-0262 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Adverse Events; Serious Adverse Event; Prior and Concomitant Medications

- 9/3/19 - 1 form, 8 itemgroups, 61 items, 1 language
Itemgroups: Administrative, Are there any non-serious adverse events to report?, Non-Serious adverse Events, Serious Adverse Event #1, Serious Adverse Event #1 - Relevant Laboratory Data, Serious Adverse Event #1 - Signature, Prior and Concomitant Medications, Prior and Concomitant Medications
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Breast Cancer NCT01306032 Registration - Eligibility/Pre-Registration Worksheet - 3158687v1.0 - Eligibility/Pre-Registration Worksheet

- 1/9/15 - 1 form, 6 itemgroups, 61 items, 1 language
Itemgroups: STANDARD PATIENT IDENTIFIER, STANDARD DEMOGRAPHICS (II), INCLUSION CRITERIA, EXCLUSION CRITERIA, Pre Study Evaluations, Laboratory studies will be conducted 1 week prior to starting study drug will include
Eligibility/Pre-Registration Worksheet ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=94CE0410-6594-C0F7-E040-BB89AD4342BD

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course -- Prior to next Course (Day 25 - 28) - Review of Disease Status; Therapeutic Interventions; End of Course Eligibility; Unscheduled Laboratory Tests; Therapeutic Interventions Log

- 9/2/19 - 1 form, 7 itemgroups, 23 items, 1 language
Itemgroups: Administrative, Review of Disease Status, Therapeutic Interventions, End of Course Eligibility, Unscheduled Laboratory Tests - Hematology, Unscheduled Laboratory Tests - Hematology, Therapeutic Interventions
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial